Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02431325 · ClinicalTrials.gov registry record · Phase 2
A Study of the Gut Barrier and Blood Vessel Inflammation in Individuals With and Without HIV
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT02431325: Completed Phase 2 study, sponsored by Massachusetts General Hospital.
NCT02431325 is a Phase 2 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 32 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02431325, a Phase 2 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
The purpose of this research study is to determine whether teduglutide can repair a "leaky" gut, decrease inflammation, and prevent or treat plaque, a build-up of fat and other materials in the blood vessels of the heart, in people with HIV. HIV disease is linked to inflammatory changes and leakiness of the gut. These changes or conditions may increase the risk of developing heart and blood vessel disease. The investigators believe teduglutide can help repair the gut barrier in people with HIV, leading to a decrease in inflammation and plaque in the blood vessels of the heart.
Interventions
- DRUG Placebo
- DRUG Teduglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2015-12 |
| Est. Completion | 2021-01-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02431325
The ClinicalTrials.gov registry entry for NCT02431325 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02431325 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02431325 about?
NCT02431325 is a clinical study titled "A Study of the Gut Barrier and Blood Vessel Inflammation in Individuals With and Without HIV". The purpose of this research study is to determine whether teduglutide can repair a "leaky" gut, decrease inflammation, and prevent or treat plaque, a build-up of fat and other materials in the blood vessels of the heart, in people with HIV. HIV disease is linked to inflammatory changes and leakines...
What is the current status of trial NCT02431325?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2015-12. Estimated completion is 2021-01-21.
What interventions are being tested in trial NCT02431325?
The interventions under investigation include: Placebo (DRUG), Teduglutide (DRUG).
Who is sponsoring clinical trial NCT02431325?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.